Breaking into the global pharmaceutical market
2026-01-22
https://pharmaphorum.com/r-d/breaking-into-the-global-pharmaceutical-market-rudacure/
RudaCure is a four-year-old biotech company based in the South Korea, focusing on ocular disease and chronic pain with a pair of potentially first-in-class drugs. The company recently raised $16.5 million in Series A funding and has partnered with Hanlim Pharmaceuticals, a local pharma company, to develop and distribute its drug candidate for Dry Eye Disease.
The company recently incorporated in the US and is participating in a MassChallenge accelerator programme via a partnership between MassChallenge, Korea’s Bio I-Corps programme and the Korean Innovation Center in Washington. They’ve also begun attending US-based events like JP Morgan, to start to make the connections that will help them sell and develop their products on a global scale.
RudaCure is a four-year-old biotech company based in the South Korea, focusing on ocular disease and chronic pain with a pair of potentially first-in-class drugs. The company recently raised $16.5 million in Series A funding and has partnered with Hanlim Pharmaceuticals, a local pharma company, to develop and distribute its drug candidate for Dry Eye Disease.
The company recently incorporated in the US and is participating in a MassChallenge accelerator programme via a partnership between MassChallenge, Korea’s Bio I-Corps programme and the Korean Innovation Center in Washington. They’ve also begun attending US-based events like JP Morgan, to start to make the connections that will help them sell and develop their products on a global scale.
